The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Patient-reported outcomes in FLT3-mutated AML patients treated with gilteritinib plus azacitidine
Eunice Wang, MD, Roswell Park Comprehensive Cancer Center, Buffalo, NY, shares an update from the LACEWING trial (NCT02752035), which investigated gilteritinib plus azacitidine versus azacitidine monotherapy in patients with newly diagnosed acute myeloid leukemia (AML) with FLT3 mutation ineligible for intensive chemotherapy. In this video, Dr Wang highlights some findings on patient-reported outcomes in this study, including quality of life, adverse events, and fatigue, and reports that there were no overall changes in these outcomes across the course of therapy. This interview took place at the 63rd ASH Annual Meeting and Exposition congress, Atlanta, GA, 2021.
